This is an aggregated industry headline. Read the full story at FierceBiotech →
Insilico keeps partnership sprint apace in $600M biobucks collab with Takeda
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on discovery of assets across Takeda's therapeutic areas of interest.
By FierceBiotech
· Jul 2, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView's corporate reputatio…
The WeekBriefing
Tzield gains accelerated approval to delay insulin decline in children 8–17 with recently diagnosed Stage 3 ty…
The WeekPharmaceutical Technology ↗
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Phar…